Sun Pharma Advanced Research Company Limited (SPARC)
Micro CapPharma stocks · Micro cap · NSE
Sun Pharma Advanced Research Company Limited (SPARC) is an Indian listed company. The provided document is an administrative notice regarding an upcoming investor presentation scheduled for January 08, 2026.
One read, four checks
75+ is strong, 60-74 is usable, 45-59 is mixed, and below 45 needs caution. These are research lenses, not buy/sell instructions.
Mixed fundamentals, management trust is acceptable, price trend is neutral, and recent execution is weak.
Fundamental lens: valuation, quality, growth, balance sheet, and cash flow.
low confidence · 0/0 claims checked
Timing lens: price trend and sector relative strength.
Rolling lens: recent quarterly delivery, not the latest single-result score.
Quarter ended 30 Jun 2026
Average · 45/100Rev +300% YoY · margin expansion
| Metric | This quarter | YoY | QoQ |
|---|---|---|---|
| Revenue | ₹40 Cr | +300.0% | -97.8% |
| EBITDA | ₹-34 Cr | +34.6% | -101.9% |
| Operating margin | -85.0% | +45500 bps | -18100 bps |
| PAT | ₹-21 Cr | NDF | -101.2% |
| PAT margin | -52.5% | +46750 bps | -14754 bps |
NDF means not disclosed in the current structured filing feed. It is intentionally not treated as zero.
Business & thesis
Growth engines, tailwinds/headwinds, and risk radar from management commentary
Business & thesis
Growth engines, tailwinds/headwinds, and risk radar from management commentary
Where growth can come from, and what can break the case
No financial or operational results were disclosed in the provided investor presentation cover letter.
The provided document is a cover letter for an investor presentation and contains no financial results, operational data, or management commentary. Therefore, no assessment of the company's thesis can be made based on this document.
Management accountability
What management said, and what results must prove
Management accountability
What management said, and what results must prove
What management said, and what results must prove
Issuer guidance and extracted claims are tracked against later reported outcomes. Treat these as management statements, not IndiaPulse forecasts.
The document does not contain any financial or operational results, making it impossible to determine a relevant comparison basis. A default of YoY is used, but no data supports this.
Numbers and claims to verify in the next filings
| Checkpoint | Current evidence | What to verify next |
|---|
Verification checkpoints are IndiaPulse research interpretation, not investment advice.
Trend score and candlestick chart
54NeutralSMA20 -10.7% / mo · MACD + · sector +2.2pp vs Nifty (3M)
Technical chart
SPARCdaily · 1Y · AUTO+60.8%Daily technical trend read
Mixed signalsSignals are conflicting — long-term uptrend intact. RSI 45. Wait for confirmation.
- Price above SMA200 (long-term uptrend) but mid-term MAs not aligned.
- SMA20 falling (~11.9% over last month) — short-term momentum negative.
- RSI(14) at 45 — falling, no extreme reading.
- MACD above signal, histogram expanding — bullish momentum building.
- 31% off 52W high · 85% above 52W low.
Mechanical read from the price + indicator series above. Not a recommendation — technical setups can reverse without warning, especially around earnings and macro events.
Valuation & score drivers
U-Score 54 · FAIR VALUE · pillar breakdown, sector model, fair-value anchor
Valuation & score drivers
U-Score 54 · FAIR VALUE · pillar breakdown, sector model, fair-value anchor
Fundamental score breakdown
FAIR VALUEWhy this score?
Top U-Score contributors and drags from the latest stored fundamentals.
Positive drivers
- Quality contributes 20/20 to the score.
- Valuation contributes 21/30 to the score.
- Balance sheet contributes 9/15 to the score.
Main drags
- Cash flow is weaker at 0/10; verify the latest quarterly trend.
- Growth is weaker at 3/25; verify the latest quarterly trend.
- Balance sheet is weaker at 9/15; verify the latest quarterly trend.
Healthcare valuation: PE/EVEBITDA with regulatory and pipeline checks
Healthcare valuation needs both earnings quality and regulatory/pipeline context.
Stored run vs live recompute
This shows the stored score trend when snapshots exist, and also compares the latest stored nightly score with a live recompute from current fundamentals and price.
Score history
12 stored score snapshots. Latest stored move: -2 points.
Factor attribution
Modelled fair value
Trust score
Does management behaviour match later outcomes? Claim delivery, forensic breakdown, evidence depth
Trust score
Does management behaviour match later outcomes? Claim delivery, forensic breakdown, evidence depth
Trust asks: does management behaviour match later outcomes? Higher is better, but confidence and evidence depth matter as much as the number.
Mixed Trust: Claim history is still being built. It ranks around the 45th percentile of the scored universe and 33rd percentile within Pharma. Main check: cash conversion is weak at 28/100.
Healthy Trust Lite: Promoter holding is 65.7%. Key concern: Operating cash flow is negative at ₹-239 Cr.
Usable, but needs evidence. Treat guidance with a margin of safety.
overall median 67 · Pharma: 33rd pctile, median 70 · Micro: 27th pctile, median 73
47 documents have extracted text, but claim history is not strong enough yet.
0 claims extracted · No contradicted claim yet
How to read this Trust Score
Mixed Trust · low confidenceRead Trust alongside U-Score, result consistency, and technical trend. A cheap stock with weak Trust needs a larger margin of safety; a high Trust score does not make an expensive stock attractive by itself.
Forensic breakdown
Read low sub-scores as due-diligence warnings, not automatic sell signals.
Trust positives
- ▸Promoter holding is 65.7%.
- ▸Promoter pledge is zero.
- ▸ROCE is 164%.
Trust risks
- ▸Operating cash flow is negative at ₹-239 Cr.
- ▸Only 0 years of positive FCF.
- ▸OPM spread across recent quarters is 932%.
Trust Lite uses financial behaviour only. Prefer claim-tested Trust when enough concall claims have later outcomes.
Financials
Full fundamentals table and 10-year revenue / profit / ROE history
Financials
Full fundamentals table and 10-year revenue / profit / ROE history
Fundamentals
Valuation
- P/E
- 4.05
- P/B
- 4.82
- EV/EBITDA
- 4.32
- Market Cap
- 6473.00Cr
Profitability
- ROE
- 279.00%
- ROCE
- 164.00%
- ROA
- 72.96%
- Dividend Y
- —
Growth (CAGR)
- Revenue 5Y
- -8.00%
- EPS 5Y
- -8.00%
- Revenue 3Y
- -16.00%
- EPS 3Y
- -20.00%
Balance Sheet
- Debt/Equity
- 0.42
- Interest Coverage
- 44.92×
- Altman Z
- 8.24
- Book Value
- 41.30
Cash Flow
- FCF Yield
- —
- FCF Positive Y
- 0/5
- OCF
- -239.00 Cr
- EPS TTM
- 48.81
Shareholding
- Promoter Hold
- 65.68%
- Promoter Pledge
- 0.00%
- Momentum 52W
- 50%
Financial History
Updated 5/9/2026
Revenue
₹ CrNet Profit
₹ CrReturn on Equity
%Peers
Business-comparable names in Pharma, ranked by similarity
Peers
Business-comparable names in Pharma, ranked by similarity
Peers
Business-comparable peers in Pharma — ranked by industry, sub-sector, theme-tag overlap, market cap, and U-Score similarity. Green cells mark the best available peer metric in this table.